NDC-11 (Package) (Ascending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
57894-0100-60 | 57894-0100 | NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE | AKEEGA | 500.0 mg/1, 100.0 mg/1 | Chemotherapy | Androgen Receptor Inhibitor, Enzyme Inhibitor | CYP17, PARP | Oral | Aug. 11, 2023 | In Use | |
57894-0111-01 | 57894-0111 | ciltacabtagene autoleucel | CARVYKTI | 100000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Feb. 28, 2022 | In Use | |
57894-0111-02 | 57894-0111 | ciltacabtagene autoleucel | CARVYKTI | 100000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Feb. 28, 2022 | In Use | |
57894-0150-12 | 57894-0150 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 28, 2011 | In Use | |
57894-0150-25 | 57894-0150 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Sept. 1, 2015 | Aug. 31, 2018 | In Use |
57894-0155-12 | 57894-0155 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Feb. 9, 2018 | In Use | |
57894-0184-12 | 57894-0184 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 17, 2017 | April 18, 2017 | No Longer Used |
57894-0195-06 | 57894-0195 | Abiraterone Acetate | Zytiga | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 17, 2017 | In Use | |
57894-0195-15 | 57894-0195 | Abiraterone Acetate | Zytiga | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 17, 2017 | In Use | |
57894-0199-06 | 57894-0199 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | March 5, 2018 | Sept. 2, 2021 | In Use |
Found 10,000 results in 7 milliseconds — Export these results